Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 839-847

  Lee, Jaehyung ^a   Gollahon, Lauren ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotide; NIMA related kinase 2; Paclitaxel; Small interfering RNA; Triple negative breast cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; NIMA RELATED KINASE 2; PACLITAXEL; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL VIABILITY; CELLULAR DISTRIBUTION; CENTROSOME; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; MITOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPINDLE APPARATUS;

EID: 84873678933     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1788     Document Type: Article

References (37)

1. Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998. (Pubitemid 28311914)
2. Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244, 2007. (Pubitemid 46291713)
3. Rakha EA and Ellis IO: Triple-negative/basal-like breast cancer: review. Pathology 41: 40-47, 2009.
4. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer - current status and future directions. Ann Oncol 20: 1913-1927, 2009.
5. Carey L, Winer E, Viale G, Cameron D and Gianni L: Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692, 2010.
6. Pérez de Castro I, de Cárcer G, Montoya G and Malumbres M: Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol 8: 375-383, 2008.
7. Chi YH and Jeang KT: Aneuploidy and cancer. J Cell Biochem 102: 531-538, 2007.
8. Kops GJ, Weaver BA and Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785, 2005. (Pubitemid 41400777)
9. Yuen KW, Montpetit B and Hieter P: The kinetochore and cancer: what's the connection? Curr Opin Cell Biol 17: 576-582, 2005. (Pubitemid 41540405)
10. Fry AM, Mayor T and Nigg EA: Regulating centrosomes by protein phosphorylation. Curr Top Dev Biol 49: 291-312, 2000.
11. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32, 2001. (Pubitemid 33676958)
12. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R and Miyakawa I: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 169: 41-49, 2001. (Pubitemid 32532095)
13. Holtrich U, Wolf G, Bräuninger A, et al: Induction and down regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 91: 1736-1740, 1994. (Pubitemid 24080280)
14. Li D, Zhu J, Firozi PF, et al: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9: 991-997, 2003. (Pubitemid 36323702)
15. Bettencourt-Dias M and Glover DM: Centrosome biogenesis and function: centrosomics brings new understanding. Nat Rev Mol Cell Biol 8: 451-463, 2007. (Pubitemid 46809152)
16. Krämer A, Neben K and Ho AD: Centrosome aberrations in hematological malignancies. Cell Biol Int 29: 375-383, 2005. (Pubitemid 40981996)
17. Nigg EA: Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2: 815-825, 2002. (Pubitemid 37328900)
18. Schultz SJ, Fry AM, Sütterlin C, Ried T and Nigg EA: Cell cycle dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. Cell Growth Differ 5: 625-635, 1994. (Pubitemid 24252327)
19. Fry AM, Schultz SJ, Bartek J and Nigg EA: Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J Biol Chem 270: 12899-12905, 1995.
20. Fry AM, Meraldi P and Nigg EA: A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 17: 470-481, 1998. (Pubitemid 28045488)
21. Faragher AJ and Fry AM: Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell 14: 2876-2889, 2003. (Pubitemid 36871528)
22. Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM and Fry AM: The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 64: 7370-7376, 2004. (Pubitemid 39372076)
23. Tsunoda N, Kokuryo T, Oda K, et al: Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci 100: 111-116, 2009.
24. Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y and Hamaguchi M: Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res 67: 9637-9642, 2007. (Pubitemid 47621209)
25. Crown J and Pegram M: Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 79 (Suppl 1): S11-S18, 2003. (Pubitemid 36801906)
26. Wei R, Ngo B, Wu G and Lee WH: Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell 22: 3584-3594, 2011.
27. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004. (Pubitemid 38525281)
28. Blajeski AL, Kottke TJ and Kaufmann SH: A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 270: 277-288, 2001. (Pubitemid 33030166)
29. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ and Hickson ID: Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1400: 121-137, 1998. (Pubitemid 28475099)
30. Nitiss JL and Beck WT: Antitopoisomerase drug action and resistance. Eur J Cancer 32A: 958-966, 1996.
31. Spallarossa P, Altieri P, Aloi C, et al: Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 297: H2169-H2181, 2009.
32. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296: 1000-1004, 2002.
33. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M and Strebhardt K: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863-1877, 2002. (Pubitemid 36104631)
34. Tsui P, Rubenstein M and Guinan P: siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer. In Vivo 19: 653-656, 2005. (Pubitemid 40903257)
35. Lou Y, Yao J, Zereshki A, et al: NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling. J Biol Chem 279: 20049-20057, 2004. (Pubitemid 38623449)
36. Fletcher L, Cerniglia GJ, Yen TJ and Muschel RJ: Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B. Biochim Biophys Acta 1744: 89-92, 2005.
37. Prime G and Markie D: The telomere repeat binding protein Trf1 interacts with the spindle checkpoint protein Mad1 and Nek2 mitotic kinase. Cell Cycle 4: 121-124, 2005. (Pubitemid 41038940)